share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  08/28 18:09

Moomoo AI 已提取核心訊息

TransCode Therapeutics, Inc., a biotech company listed on the Nasdaq Capital Market, is facing potential delisting due to non-compliance with Nasdaq's listing requirements. The company received two deficiency letters from Nasdaq. The first, received on August 13, 2024, indicated that TransCode's common stock had not met the minimum bid price of $1.00 per share for 30 consecutive business days. The second letter, received on August 15, 2024, notified the company of its failure to meet the minimum stockholders' equity requirement of $2.5 million, with its equity standing at $1,322,274 as of June 30, 2024. Despite raising approximately $2.4 million in a July 2024 equity offering, there is no guarantee that Nasdaq will consider the company's stockholders' equity on a pro forma basis. TransCode does not meet alternative quantitative standards for continued listing either. The company has appealed the delisting decision and a hearing with the Nasdaq Hearings Panel is scheduled for October 1, 2024. The delisting action has been stayed pending the Panel's final decision, but there is no assurance that the company will regain compliance or avoid delisting.
TransCode Therapeutics, Inc., a biotech company listed on the Nasdaq Capital Market, is facing potential delisting due to non-compliance with Nasdaq's listing requirements. The company received two deficiency letters from Nasdaq. The first, received on August 13, 2024, indicated that TransCode's common stock had not met the minimum bid price of $1.00 per share for 30 consecutive business days. The second letter, received on August 15, 2024, notified the company of its failure to meet the minimum stockholders' equity requirement of $2.5 million, with its equity standing at $1,322,274 as of June 30, 2024. Despite raising approximately $2.4 million in a July 2024 equity offering, there is no guarantee that Nasdaq will consider the company's stockholders' equity on a pro forma basis. TransCode does not meet alternative quantitative standards for continued listing either. The company has appealed the delisting decision and a hearing with the Nasdaq Hearings Panel is scheduled for October 1, 2024. The delisting action has been stayed pending the Panel's final decision, but there is no assurance that the company will regain compliance or avoid delisting.
TransCode Therapeutics, Inc.是一家在納斯達克資本市場上市的生物技術公司,由於不符合納斯達克的上市要求,面臨潛在退市風險。該公司收到了兩封納斯達克的不符合要求函。第一封函件於2024年8月13日收到,指出TransCode的普通股在連續30個交易日內未達到每股1.00美元的最低買盤價。第二封函件於2024年8月15日收到,通知該公司其未能達到250萬美元的最低股東權益要求,截至2024年6月30日,其股本爲1,322,274美元。儘管該公司在2024年7月進行了約240萬美元的股權發行,但無法保證納斯達克將考慮公司的股東權益以推演的方式計算。TransCode也未符合繼續上市的備選定量標準。該公司已對退市決定提起上訴,與納斯達克聽證會的聽證已定於2024年10月1日舉行。退市行動暫停,等待聽證會委員會的最終決定,但不能保證該公司能恢復合規或避免退市。
TransCode Therapeutics, Inc.是一家在納斯達克資本市場上市的生物技術公司,由於不符合納斯達克的上市要求,面臨潛在退市風險。該公司收到了兩封納斯達克的不符合要求函。第一封函件於2024年8月13日收到,指出TransCode的普通股在連續30個交易日內未達到每股1.00美元的最低買盤價。第二封函件於2024年8月15日收到,通知該公司其未能達到250萬美元的最低股東權益要求,截至2024年6月30日,其股本爲1,322,274美元。儘管該公司在2024年7月進行了約240萬美元的股權發行,但無法保證納斯達克將考慮公司的股東權益以推演的方式計算。TransCode也未符合繼續上市的備選定量標準。該公司已對退市決定提起上訴,與納斯達克聽證會的聽證已定於2024年10月1日舉行。退市行動暫停,等待聽證會委員會的最終決定,但不能保證該公司能恢復合規或避免退市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息